Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STENO INTEN-CT: Screening and intervention for subclinical coronary artery disease in type 2 diabetes
2022-500143-21-01Phase 4Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide and dapagliflozin in type 2 diabetes mellitus (T2DM), coronary arteriosclerosis, heart failure (HF) and 3 more (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Composite cardiovascular endpoint. Planned start Jul 2022; status: authorised.
02
Drugs
semaglutidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosisheart failure (HF)strokearteriosclerosis obliterans
Beyond the preview
Go deeper on 2022-500143-21-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500143-21-01.